| Patents for A61K 38 - Medicinal preparations containing peptides (316,240) |
|---|
| 01/20/2011 | US20110014177 Methods for Enhancing Physical and Mental Energy |
| 01/20/2011 | US20110014176 Compounds and method for reducing uric acid |
| 01/20/2011 | US20110014175 Stimulation of the synthesis of the activity of an isoform of lysl oxidase-like loxl for stimulating the formation of elastic fibres |
| 01/20/2011 | US20110014174 Lysozyme, A Novel Vasodilator of Sepsis that can be inhibited by a Peroxidase and Hydroxyl Radical Scavengers |
| 01/20/2011 | US20110014173 Axl tyrosine kinase inhibitors and methods of making and using the same |
| 01/20/2011 | US20110014172 Recombinant Human CLN2 Protein and Methods of Its Production and Use |
| 01/20/2011 | US20110014169 High affinity ny-eso t cell receptors |
| 01/20/2011 | US20110014158 Compositions and methods of using chondroitinase abci mutants |
| 01/20/2011 | US20110014155 Reovirus for the Treatment of Cellular Proliferative Disorders |
| 01/20/2011 | US20110014154 Aromatic Heterocyclic Fused Indolobenzadiazepine HCV NS5B Inhibitors |
| 01/20/2011 | US20110014153 Reinforced tissue graft |
| 01/20/2011 | US20110014152 Increased t-cell tumor infiltration and eradication of metastases by mutant light |
| 01/20/2011 | US20110014128 Cytokine receptor modulators, method of identifying same, and method of modulating cytokine receptors activity with same |
| 01/20/2011 | US20110014124 Targeted atherosclerosis treatment |
| 01/20/2011 | US20110014123 RNA interference mediating small RNA molecules |
| 01/20/2011 | US20110014118 Nanotherapeutic colloidal metal compositions and methods |
| 01/20/2011 | DE112009000300T5 Therapeutische Peptidomimetische Makrocyclen Therapeutic Peptidomimetic macrocycles |
| 01/20/2011 | CA2803061A1 Vaccines and compositions against streptococcus pneumoniae |
| 01/20/2011 | CA2768299A1 Bifunctional stapled polypeptides and uses thereof |
| 01/20/2011 | CA2767858A1 Unit dose formulation of antidotes for factor xa inhibitors and methods of using the same |
| 01/20/2011 | CA2767826A1 Mesenchymal stem cell differentiation using aniopoietin-like-3 |
| 01/20/2011 | CA2767792A1 Acylated glucagon analogues |
| 01/20/2011 | CA2767760A1 Process and system for obtaining botulinum neurotoxin |
| 01/19/2011 | EP2275818A2 Method for improved early recognition of the seroconversion of an antibody to hepatitis C |
| 01/19/2011 | EP2275575A2 Coding sequence haplotypes of the human BRCA2 gene |
| 01/19/2011 | EP2275574A2 Coding sequence haplotypes of the human BRCA2 gene |
| 01/19/2011 | EP2275573A1 Antibodies for treating and diagnosing gastric adenocarcinoma |
| 01/19/2011 | EP2275572A2 Identification of surface-associated Antigenes used for the diagnosis and therapy of tumours |
| 01/19/2011 | EP2275571A2 Identification of surface-associated Antigenes used for the diagnosis and therapy of tumours |
| 01/19/2011 | EP2275570A2 Identification of surface-associated Antigenes used for the diagnosis and therapy of tumours |
| 01/19/2011 | EP2275557A1 Albumin fusion proteins |
| 01/19/2011 | EP2275549A1 Compositions and methods for the diagnosis and treatment of disorders involving angiogenesis |
| 01/19/2011 | EP2275548A1 Mammalian cytokine receptor subunit proteins, related reagents and methods |
| 01/19/2011 | EP2275544A2 Genes and polypeptides relating to human colon cancers |
| 01/19/2011 | EP2275536A1 AP1 amine oxidase variants |
| 01/19/2011 | EP2275450A1 Treatment with anti-ERBB2 antibodies |
| 01/19/2011 | EP2275447A1 Methods of inhibiting metastasis |
| 01/19/2011 | EP2275441A1 High affinity HIV T cell receptors |
| 01/19/2011 | EP2275440A2 Growth factor-mimicking peptides and uses thereof |
| 01/19/2011 | EP2275439A2 Novel insulin derivatives |
| 01/19/2011 | EP2275438A1 Glucagon-like peptide-2 analogs |
| 01/19/2011 | EP2275437A1 Polypeptide and pharmaceutical composition containing the polypeptide |
| 01/19/2011 | EP2275433A1 Metastin derivative and use thereof |
| 01/19/2011 | EP2275401A1 Crystalline 1-{[(a-isobutanoyloxyethoxy)carbonyl]aminomethyl}-1-cyclohexane acetic acid |
| 01/19/2011 | EP2275138A1 Promoter for bicarbonate secretion in gastrointestinal tract |
| 01/19/2011 | EP2275136A1 Combination therapies for B-cell lymphomas comprising administration of anti-CD20 antibody |
| 01/19/2011 | EP2275119A1 Stable isotonic lyophilized protein formulation |
| 01/19/2011 | EP2275118A2 Pancreas-specific proteins |
| 01/19/2011 | EP2275117A1 GLP-1, exendin-4, peptide analogs and uses thereof |
| 01/19/2011 | EP2275116A1 Use of a Pak inhibitor for the treatment of a joint disease |
| 01/19/2011 | EP2275115A2 Inhibition of stress-induced ligand-dependent EGFR activation |
| 01/19/2011 | EP2275114A1 Pharmaceutical composition for treating or preventing cancer which induces dendritic cell-like differentiation of monocytes to increase anticancer immune activity |
| 01/19/2011 | EP2275110A2 Cladribine regimen for treating Multiple Sclerosis |
| 01/19/2011 | EP2275104A2 Pharmaceutical and cosmetic composition including lactoferrin, ciclopirox and etidronic acid |
| 01/19/2011 | EP2275103A2 mTOR inhibitors in the treatment of endocrine tumors |
| 01/19/2011 | EP2275086A1 Reduced volume formulation of glatiramer acetate and methods of administration |
| 01/19/2011 | EP2274978A1 Methods for treatment of insulin-like growth factor-I(IGF-I) deficiency |
| 01/19/2011 | EP2274432A1 A method for the production of a human protein in a plant, in particular a human recombinant lysosomal enzyme in a cereal endosperm |
| 01/19/2011 | EP2274330A1 Peptides and derivatives thereof, the manufacturing thereof as well as their use for preparing a therapeutically and/or preventively active pharmaceutical composition |
| 01/19/2011 | EP2274329A1 Peptides and derivatives thereof, the manufacturing thereof as well as their use for preparing a therapeutically and/or preventively active pharmaceutical composition |
| 01/19/2011 | EP2274328A1 Peptides, peptidomimetics and derivatives thereof, the manufacturing thereof as well as their use for preparing a therapeutically and/or preventively active pharmaceutical composition |
| 01/19/2011 | EP2274326A1 Suppressor of the endogenous interferon- gamma |
| 01/19/2011 | EP2274324A1 Substances and compositions for enhancing dna repair and methods of use |
| 01/19/2011 | EP2274053A2 Use of the human pancreatic polypeptide as a therapeutic agent |
| 01/19/2011 | EP2274006A2 Angiostatic compositions comprising truncated tyrosyl-trna synthetase polypeptides and methods of using same |
| 01/19/2011 | EP2274005A2 Treatment of tumors |
| 01/19/2011 | EP2274004A2 In vivo temporal control of activ at able matrix- degrading enzymes |
| 01/19/2011 | EP2274003A1 Composition and method for the inhibition of postoperative adhesions severity |
| 01/19/2011 | EP2274002A2 Leucine-rich peptide compositions and methods for isolation |
| 01/19/2011 | EP2274001A2 Heat shock protein gp96 vaccination and methods of using same |
| 01/19/2011 | EP2273989A1 Combination therapy for the treatment of bacterial infections |
| 01/19/2011 | EP2273976A2 Treatment of bladder dysfunction using liposomal botulinum toxin |
| 01/19/2011 | EP2273969A1 Topical composition for external use and process for producing the same |
| 01/19/2011 | EP2155229B1 Composition for transmucosal delivery of polypeptides |
| 01/19/2011 | EP1906987B1 Methods and compositions for emergency contraception using endothelin receptor antagonists |
| 01/19/2011 | EP1802649B1 Solid phase peptide sythesis |
| 01/19/2011 | EP1781688B1 Compounds for proteasome enzyme inhibition |
| 01/19/2011 | EP1773867B1 Proteinaceous compounds and uses therefor |
| 01/19/2011 | EP1693456B1 Method of identifying modulators of a g protein-coupled receptor |
| 01/19/2011 | EP1644501B1 Ssx-2 peptides presented by hla class ii molucules |
| 01/19/2011 | EP1600507B1 Mutant SREBP-1c promoters and use thereof |
| 01/19/2011 | EP1556071B1 Methods to prevent tumor recurrence by blockade of tgf-beta |
| 01/19/2011 | EP1506230B1 Soluble formulations comprising monomeric insulin and acylated insulin |
| 01/19/2011 | EP1411962B1 Monoclonal antibody therapy for pancreas cancer |
| 01/19/2011 | EP1409008B1 Use of a nucleic acid molecule coding the disintegrin domain of an adamalysin as anti-angiogenic, anti-invasive and anti-metastatic agent |
| 01/19/2011 | EP1325019B1 Antisense modulation of clusterin expression |
| 01/19/2011 | EP1252300B1 Nucleic acid molecules encoding transmembrane serine proteases, the encoded proteins and methods based thereon |
| 01/19/2011 | EP1224299B1 Recombinant proteins and peptides for endotoxin biosensors, endotoxin removal, and anti-microbial and anti-endotoxin therapeutics |
| 01/19/2011 | EP1185296B1 Prevention and treatment of amyloidogenic diseases |
| 01/19/2011 | CN101952316A Cadherin-11 ECl domain antagonists for treating inflammatory joint disorders |
| 01/19/2011 | CN101952309A Protease inhibitor |
| 01/19/2011 | CN101952306A Cosmetic and dermatological formulations of MNTF peptides |
| 01/19/2011 | CN101952302A New polypeptides having affinity for HER2 |
| 01/19/2011 | CN101952016A Recombinant VWF formulations |
| 01/19/2011 | CN101951957A Insulin formulations for insulin release as a function of tissue glucose levels |
| 01/19/2011 | CN101951955A Pharmaceutical composition for cancer treatment |
| 01/19/2011 | CN101951945A Compositions and methods for treatment of microbial disorders |
| 01/19/2011 | CN101951944A Topical application and formulation of erythropoietin for skin wound healing |
| 01/19/2011 | CN101951943A NGF conjugates and uses thereof |
| 01/19/2011 | CN101951942A Mntf peptide compositions and methods of use |